INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo SPIDER ANTIVENOM

SPIDER VENOM ANTISERUM

PROPRIETARY NAME:
SPIDER ANTIVENOM

DESCRIPTIVE NAME:
Refined Equine Antispider Serum globulins.

REGISTRATION NUMBER:
T519 (Act 101/1965)

PHARMACOLOGICAL CLASSIFICATION:
A30.2 Antibodies

SCHEDULING STATUS:
S4

COMPOSITION:
Button Spider Venom Antiserum 5 mL, Cresol 0,3% as Preservative.

IDENTIFICATION:
Clear, almost colourless or faintly yellow liquid, having a slight odour due to the preservative.

PHARMACOLOGICAL ACTION:
Neutralises the venoms of the button spiders Latrodectus species.

INDICATIONS:
Used for treatment of the bite of button spiders. Antiserum should only be used where there is severe pain, shock or collapse. Not intended to protect against bites of other species.

CONTRA-INDICATIONS:
Should be used with great caution if patient is subject to allergic diseases such as asthma or infantile eczema, or was allergic to any previous antiserum injection.

DOSAGE AND DIRECTIONS FOR USE:
Inject 5 mL intravenously or intramuscularly at the earliest sign of poisoning. If relief has not been obtained in an hour or two, or if the condition of the patient deteriorates, more antivenom, 5 mL or 10 mL, should be injected.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Reactions are liable to occur after the injection of any serum of animal origin. Anaphylaxis may occur in rare cases, with hypotension, dyspnoea, urticaria, and shock. Anaphylactic reactions should be treated with adrenaline, possibly in association with antihistamine and corticosteroid therapy.
Serum sickness may occur 7 to 10 days after the injection of serum of animal origin; symptoms include fever, vomiting, diarrhoea, bronchospasm, and urticaria. Nephritis, myocarditis, neuritis, polyarthritis, and uveitis have been reported as rare complications of serum sickness.

If there is no history of previous serum injection or allergic reaction, the dose of serum may be given intramuscularly. If the patient is subject to allergic diseases, a trial dose of serum may be given intramuscularly. If the patient is subject to allergic diseases, a trial dose of 0,2 mL (diluted 1:10 if preferred) of the serum should be given subcutaneously; if no general reaction develops within 30 minutes, the main dose may be given intravenously or intramuscularly. The patient must be kept under observation for at least 30 minutes after the injection and an adrenaline injection kept in readiness for emergency use.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
None known

PRESENTATION:
Packed singly in ampoules containing 5 mL.

STORAGE INSTRUCTIONS:
Store at 2° C to 10° C. DO NOT FREEZE. Protect from light.

NAME AND BUSINESS ADDRESS OF APPLICANT:
The South African Institute for Medical Research.
Rietfontein, Edenvale, Transvaal.

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
June 1990

150-592

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996,1997,1998